Approval · Notice of Compliance 20691 · 2018
XGEVA: Notice of Compliance 20691
Issued April 4, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20691
- Date
- April 4, 2018
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: xgeva (denosumab) is indicated for reducing the risk of developing skeletal-related events in patients with multiple myeloma
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XGEVA | Not yet assigned | — |
Medicinal ingredients
- DENOSUMAB 70 MG per ML